| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbd8393ece7c40b8e7193b4078f53b0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0db5a7d0af0d0ae5738157315366981f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715 |
| filingDate |
2009-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ed18235327a9c1ec0d0137888b597c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b0a0c8d5b29d44a0057a577d395160c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db5a4448275a00cd08103b6dab1ca8f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ab9c239b7a7e8a20f9fcd39912efa0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6e3d8739338b2682ff7ee7ee153bf33 |
| publicationDate |
2014-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-101883787-B |
| titleOfInvention |
A soluble tumor necrosis factor receptor mutant |
| abstract |
A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha or lymphotoxin related diseases. |
| priorityDate |
2008-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |